Foresite Capital Management V’s Nurix Therapeutics NRIX Stock Holding History

Foresite Capital Management V’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43M	Hold	265,000	–	–	1.77%	9
2026 Q1	$4.11M	Buy	+265,000	New	+$4.39M	1.52%	8
2021 Q4	–	Sell	-451,522	Closed	-$13.5M	–	18
2021 Q3	$13.5M	Hold	451,522	–	–	4.2%	8
2021 Q2	$12M	Hold	451,522	–	–	4.71%	8
2021 Q1	$14M	Hold	451,522	–	–	4.13%	7
2020 Q4	$14.8M	Buy	+451,522	New	+$15M	10.99%	4

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Foresite Capital Management V's NRIX Position: Q2 2026 in Review

Foresite Capital Management V held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 265,000 shares worth $6.43M. The position accounts for 1.77% of the portfolio, ranked #9.

Foresite Capital Management V first reported a position in NRIX in Q4 2020 and has held it in 6 quarters since. The position peaked at $14.8M in Q4 2020. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Foresite Capital Management V held 265,000 shares of Nurix Therapeutics worth $6.43M as of Q2 2026.
Foresite Capital Management V left its Nurix Therapeutics share count unchanged in Q2 2026.
Nurix Therapeutics made up 1.77% of Foresite Capital Management V's portfolio in Q2 2026, its #9 holding.
Foresite Capital Management V first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 6 quarters since.
Foresite Capital Management V's Nurix Therapeutics position peaked at $14.8M in Q4 2020.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Foresite Capital Management V's 13F filing for Q2 2026, filed 14 Aug 2026.